Skip to main content
. 2019 Aug 21;9:12184. doi: 10.1038/s41598-019-48570-x

Figure 2.

Figure 2

Molecular subtypes and administered therapy for the study cohort. (A) Proportions of subtypes from four molecular subtype signatures in the complete RNAseq cohort. (B) Subtype proportions of the AIMS-PAM50 single sample predictor for patients diagnosed 2012, 2013, and 2014 respectively, illustrating the stability of the underlying patient demographics across inclusion years. (C) Treatment proportions according to national registry data for RNAseq patients diagnosed 2012, 2013, and 2014 respectively, illustrating the stability of the underlying patient demographics during inclusion years. ACT: adjuvant chemotherapy. Endocrine: endocrine treatment.